Hayakawa Y - Search Results

1

Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells.

Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJ, Hayakawa Y, Sidobre S, Keating R, Kronenberg M, Smyth MJ, Godfrey DI. Crowe NY, et al. Among authors: hayakawa y. J Immunol. 2003 Oct 15;171(8):4020-7. doi: 10.4049/jimmunol.171.8.4020. J Immunol. 2003. PMID: 14530322

2

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.

Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K. Takeda K, et al. Among authors: hayakawa y. J Exp Med. 2002 Jan 21;195(2):161-9. doi: 10.1084/jem.20011171. J Exp Med. 2002. PMID: 11805143 Free PMC article.

3

NKT cells - conductors of tumor immunity?

Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. Smyth MJ, et al. Among authors: hayakawa y. Curr Opin Immunol. 2002 Apr;14(2):165-71. doi: 10.1016/s0952-7915(02)00316-3. Curr Opin Immunol. 2002. PMID: 11869887 Review.

4

IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide.

Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I. Hayakawa Y, et al. Blood. 2002 Sep 1;100(5):1728-33. Blood. 2002. PMID: 12176894 Free article.

5

New aspects of natural-killer-cell surveillance and therapy of cancer.

Smyth MJ, Hayakawa Y, Takeda K, Yagita H. Smyth MJ, et al. Among authors: hayakawa y. Nat Rev Cancer. 2002 Nov;2(11):850-61. doi: 10.1038/nrc928. Nat Rev Cancer. 2002. PMID: 12415255 Review. No abstract available.

6

Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.

Hayakawa Y, Kelly JM, Westwood JA, Darcy PK, Diefenbach A, Raulet D, Smyth MJ. Hayakawa Y, et al. J Immunol. 2002 Nov 15;169(10):5377-81. doi: 10.4049/jimmunol.169.10.5377. J Immunol. 2002. PMID: 12421908

7

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.

Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ. Seki N, et al. Among authors: hayakawa y. Cancer Res. 2003 Jan 1;63(1):207-13. Cancer Res. 2003. PMID: 12517799

8

Nature's TRAIL--on a path to cancer immunotherapy.

Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Smyth MJ, et al. Among authors: hayakawa y. Immunity. 2003 Jan;18(1):1-6. doi: 10.1016/s1074-7613(02)00502-2. Immunity. 2003. PMID: 12530970 Free article. Review.

9

Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.

Hayakawa Y, Rovero S, Forni G, Smyth MJ. Hayakawa Y, et al. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9464-9. doi: 10.1073/pnas.1630663100. Epub 2003 Jul 16. Proc Natl Acad Sci U S A. 2003. PMID: 12867593 Free PMC article.

10

NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy.

Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ, Chambers BJ. Hayakawa Y, et al. J Immunol. 2004 Jan 1;172(1):123-9. doi: 10.4049/jimmunol.172.1.123. J Immunol. 2004. PMID: 14688317

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,194 results

Search Page

Filters